AACE released clinical guidelines on the diagnosis, management, and surveillance of tumors related to multiple endocrine neoplasia type 1.

“Pituitary tumors are the second most common manifestation. Although pancreatic neuroendocrine tumors are less prevalent, they are associated with a higher mortality risk in MEN1 patient ...

long-acting subcutaneous depot of octreotide under development for the treatment of three chronic and severe disease indications: acromegaly, gastroenteropancreatic neuroendocrine tumors (GEP-NET ...

Vitamin D’s anti-cancer powers go beyond bones, new findings reveal how it suppresses inflammation, boosts immune surveillance, and disrupts tumor development to guard against colorectal cancer.

Neuroendocrine ... tumors to our disease fund portfolio and to help ease the financial burden for people living with NETs. Thank you to our donors for addressing this critical, unmet need so NET ...

The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated advanced neuroendocrine tumors, offering a new ...

Somatostatin analogs (e.g., octreotide, lanreotide) will continue to be main therapies for functioning neuroendocrine tumors over the next years. Pasireotide, a new panreceptor analog, might ...

The data were presented by study investigator Jaume Capdevila, MD, PhD, at the 22 nd Annual European Neuroendocrine Tumor Society (ENETS ... analogues in this GEP-NET patient population.

Grade 1 or Grade 2 somatostatin receptor-positive neuroendocrine tumors of gastroenteric or pancreatic origin (Ki-67 ≤20%) in Europe, the United States, Australia and South Africa. The study ...

Adding these methyl groups enhances RNA stability; however, their removal by enzymes such as FTO can promote development of tumors. FTO was the first identified m6A demethylase and has been shown ...

GEP-NETs constitute approximately 60.9% of primary neuroendocrine ... line therapy involves SSAs (eg, octreotide or lanreotide) to control symptoms and inhibit tumor growth. Second-line and ...

The trial enrolled 309 patients with Grade 1 or Grade 2 inoperable, progressive, somatostatin receptor-positive neuroendocrine tumors of gastroenteric ... SSTR-positive GEP-NET tumors. The COMPOSE ...